A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
February 10, 2020
End Date
April 9, 2024
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
February 10, 2020
End Date
April 9, 2024